ReviewJournal of industrial microbiology & biotechnology2016
The biosynthetic pathway of FK506 and its engineering: from past achievements to future prospects.
Review in Journal of industrial microbiology & biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Engineering of FK520 polyketide synthase for rapid access to quality control reference standards.Microbial cell factories · 2025Article
- Optimization of FK-506 production in Streptomyces tsukubaensis by modulation of Crp-mediated regulation.Applied microbiology and biotechnology · 2023Article
- Optimization of the precursor supply for an enhanced FK506 production inFrontiers in bioengineering and biotechnology · 2022Article
- Genome mining for drug discovery: progress at the front end.Journal of industrial microbiology & biotechnology · 2021Review
- Improvement of FK506 production via metabolic engineering-guided combinational strategies in Streptomyces tsukubaensis.Microbial cell factories · 2021Article
- Bluemomycin, a new naphthoquinone derivative from Streptomyces sp. with antimicrobial and cytotoxic properties.Biotechnology letters · 2021Article
- Bioengineering of Anti-Inflammatory Natural Products.ChemMedChem · 2021Review
- Article
- Evaluation of carbon:nitrogen ratio in semi-defined culture medium to tacrolimus biosynthesis byBiotechnology reports (Amsterdam, Netherlands) · 2020Article
- Development of Non-Immunosuppressive FK506 Derivatives as Antifungal and Neurotrophic Agents.Journal of microbiology and biotechnology · 2020Review
- Interactions of FK506 and Rapamycin With FK506 Binding Protein 12 in Opportunistic Human Fungal Pathogens.Frontiers in molecular biosciences · 2020Review
- Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents.Nature communications · 2019Article
- Protective Effects of Nargenicin A1 against Tacrolimus-Induced Oxidative Stress in Hirame Natural Embryo Cells.International journal of environmental research and public health · 2019Article
- Natural product drug discovery in the genomic era: realities, conjectures, misconceptions, and opportunities.Journal of industrial microbiology & biotechnology · 2019Article
- A Review of the Microbial Production of Bioactive Natural Products and Biologics.Frontiers in microbiology · 2019Review
- Article
- Unraveling Nutritional Regulation of Tacrolimus Biosynthesis inAntibiotics (Basel, Switzerland) · 2018Review
- Molecular beacons to identify gifted microbes for genome mining.The Journal of antibiotics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FK506, a 23-membered macrolide produced by several Streptomyces species, is an immunosuppressant widely used to prevent the rejection of transplanted organs. In addition, FK506 and its analogs possess numerous promising therapeutic potentials including antifungal, neuroprotective, and neuroregenerative activities. Herein, we introduce the biological activities and mechanisms of action of FK506 and discuss recent progress made in understanding its biosynthetic pathway, improving production, and in the mutasynthesis of diverse analogs. Perspectives highlighting further strain improvement and structural diversification aimed at generating more analogs with improved pharmaceutical properties will be emphasized.
Indexed as
Identifiers
26342319What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.